Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCapital Bluecross Formulary Coverage & Prior Auth …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCapital BluecrossPolicy N/A

    Prescription Drug Formulary and Utilization Management

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the Capital Blue Cross Elite Full Formulary: which drugs are covered, tier placement, and utilization management (prior authorization, step therapy, quantity limits) for members and providers under Capital Blue Cross plans.

    Policy Summary
    PayerCapital Bluecross
    PolicyPrescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when required; failure to obtain PA may result in noncoverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    quarterlyformulary updates
    30-dayspecialty supply limit
    Accredospecialty pharmacy
    20+drug lines shown
    antibioticsprimary class represented

    Formulary Coverage & Exclusions

    Formulary Coverage and Utilization Management

    Covered when plan terms and utilization management criteria are met.

    Formulary and regulatory requirements: Drug must be FDA-approved (NDA, ANDA, or BLA) and be covered under the member's specific plan terms; group-specific benefits or legal requirements (e.g., preventive benefits) may supersede this policy.

    supported by document

    Prior authorization: If the formulary indicates prior authorization is required for the drug (noted with a dot in the prior authorization column), the provider must obtain prior authorization before the drug will be covered.

    PA noted with dot in formulary

    Step therapy: If the formulary indicates the drug is subject to step therapy (noted with a dot in the step therapy column), the member must trial and fail the required alternative(s) before coverage of the requested drug is available.

    Step therapy noted with dot in formulary

    Policy Summary
    PayerCapital Bluecross
    PolicyPrescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when required; failure to obtain PA may result in noncoverage.
    SourceLink
    On This Page
    Formulary Coverage & ExclusionsDrug Name / Abbreviation MappingsAuthorization, Step Therapy & Submission NotesAbbreviations & Key TermsSupply Limits & Specialty Drug SupplyAdministration & Billing NotesPolicy Background
    Quantity limits: When a drug has a quantity level limit (noted with a dot in the QLL column), coverage is limited to the specified quantity or time period; quantities beyond the limit may be the member's financial responsibility.

    QLL indicated with dot in formulary; specialty drugs limited to 30-day supply

    Nonformulary / exception process: If a drug is not listed on the formulary or is not yet FDA-approved, the provider may submit a nonformulary exception request supporting medical necessity for coverage consideration.

    Nonformulary exception available; unapproved drugs not covered

    Coverage exclusions include drugs that are not FDA-approved, products indicated for cosmetic purposes (for example, agents for hair growth or wrinkle treatment), and categories that some plans exclude such as erectile dysfunction or certain weight-loss/anti-obesity agents. Prescription products with available OTC equivalents may also be excluded. The policy notes that some drugs not approved for self-administration may be covered under the medical benefit rather than the pharmacy benefit.

    This abbreviation key section provides mappings between short tokens and full product lines and does not itself state coverage determinations, utilization management rules, or exclusions.

    The material in this segment is an abbreviation/drug mapping used for reference within the formulary tables; it does not contain coverage decision language or criteria.

    This abbreviation key block lists vaccine product name mappings and related shorthand identifiers; it does not specify coverage criteria, exclusions, or medical necessity rules.

    Drugs characterized as experimental, investigational, or not FDA-approved are explicitly stated as not covered by the prescription drug benefit.

    The abbreviation key content in this portion does not include any statements declaring products to be not medically necessary.

    Drug Name / Abbreviation Mappings

    Formulary Drug Name / Abbreviation mappingsmixed
    erythromycin ethylsuccinate for susp 400 mg/sml (Eryped 400)Listed as Drug Name / repeated in abbreviation key
    erythromycin tab delayed release 250 mg; 333 mg; 500 mgListed in abbreviation mappings
    ciprofloxacin hcl tab 750 mg (base equiv)Listed as Drug Name
    levofloxacin oral soln 25 mg/ml; levofloxacin tab 250 mg; 500 mg; 750 mgListed as Drug Name
    moxifloxacin hcl tab 400 mg (base equiv)Listed as Drug Name
    fidaxomicin tab 200 mg (Dificid)Listed as Drug Name
    OFLOXACIN ofloxacin tab 300 mg; ofloxacin tab 400 mgListed as Drug Name
    demeclocycline hcl tab 150 mg; 300 mgListed in TETRACYCLINES group
    AMINOGLYCOSIDESCategory header present
    doxycycline hyclate cap 50 mg; 100 mg (Vibramycin)Listed as Drug Name
    1–10 of 37
    1/4
    Drug name tokens in abbreviation keymixed
    DELSTRIGOdoravirine-lamivudine-tenofovir df tab 100-300-300 mg
    EPCLUSAsofosbuvir-velpatasvir pellet pack 150-37.5 mg; 200-50 mg
    DESCOVYemtricitabine-tenofovir alafenamide fumarate tab 120-15 mg
    DOVATOdolutegravir sodium-lamivudine tab 50-300 mg (base eq)
    Additional drug tokensmixed
    TRUVADAemtricitabine-tenofovir disoproxil fumarate tab 100-150 mg; 133-200 mg; 167-250 mg
    ISENTRESSraltegravir potassium various formulations
    Further drug tokensmixed
    ENTECAVIRentecavir tab 0.5 mg; 1 mg (Baraclude)
    KALETRAlopinavir-ritonavir soln 400-100 mg/ml (80-20 mg/ml)
    PREZISTAdarunavir oral susp 100 mg/ml
    Drug name entries (sample)NDC
    PREVYMISletermovir tab 240 mg
    LIVTENCITYmaribavir tab 200 mg
    PREZCOBIXdarunavir-cobicistat tab 675-150 mg, 800-150 mg
    PREZISTAdarunavir oral susp 100 mg/ml
    MAVYRETglecaprevir-pibrentasvir pellet pack 50-20 mg; tab 100-40 mg
    RELENZA DISKHALERzanamivir aerosol powder breath activated 5 mg/act
    Additional drug name entriesNDC
    SOVALDIsofosbuvir pellet pack 150 mg, 200 mg; tab 200 mg; 400 mg
    STRIBILDelvitegravir-cobicistat-emtricitabine-tenofovir DF tab
    HIV-related drug name entriesNDC
    TIVICAYdolutegravir sodium tab 50 mg; PD oral susp 5 mg
    TRIUMEQabacavir-dolutegravir-lamivudine tab 600-50-300 mg
    TYBOSTcobicistat tab 150 mg
    Antiviral entriesNDC
    valacyclovirvalacyclovir hcl tab 500 mg; 1 g (Valtrex)
    valganciclovirvalganciclovir hcl for soln 50 mg/ml; tab 450 mg (Valcyte)
    VEMLIDYtenofovir alafenamide fumarate tab 25 mg
    Drug name entries from abbreviation keyNDC|mixed
    Valtrexvalacyclovir hcl tab 1 gm (Valtrex)
    Valcytevalganciclovir hcl for soln 50 mg/mL (base equiv) and tab 450 mg (base equiv) (Valcyte)
    KRINTAFELtafenoquine succinate tab 150 mg
    VEMLIDYtenofovir alafenamide fumarate tab 25 mg
    VIREADtenofovir disoproxil fumarate oral powder 40 mg/g and tab 150 mg, 200 mg
    VOSEVIsofosbuvir-velpatasvir-voxilaprevir tab 400-100-100 mg
    XOFLUZAbaloxavir marboxil tab therapy pack 1 40 mg
    BENZNIDAZOLEbenznidazole tab 12.5 mg; 100 mg
    VIRACEPTnelfinavir mesylate tab 250 mg, 625 mg
    CAYSTONaztreonam lysine for inhalation solution 75 mg
    1–10 of 20
    1/2
    Vaccine product names listed (no explicit CPT/HCPCS codes present in these chunks)mixed
    No codes listed
    Biologicals / Vaccinesmixed
    SHINGRIXzoster vac recombinant adjuvanted for im inj 50 mcg/0.5ml
    PNEUMOVAX 23pneumococcal vaccine polyvalent soln syr pref
    PREVNAR 20pneumococcal 20-valent conjugate vaccine susp syr 0.5 ml
    RECOMBIVAX HBhepatitis b vaccine (recombinant) susp
    ROTATEQrotavirus vaccine, live oral pentavalent soln
    TRUMENBAmeningococcal group B vac (recomb) im susp prefilled syr
    BOOSTRIXtet-diph-acell pertuss ad pref syr
    Allergen immunotherapy oral tabletsmixed
    GRASTEKtimothy grass pollen allergen ext sl tab 2800 bau
    ODACTRAdust mite mixed ext sl tab 12 sq-hdm
    ORALAIRgrass mixed pollen ext sl tab 300 ir
    RAGWITEKshort ragweed pollen allergen extract sl tab 12 amb a 1-U
    Antineoplastics / Oncology oral agentsmixed
    BOSULIFbosutinib cap/tab (multiple strengths listed)
    BRAFTOVIencorafenib cap 75 mg
    BRUKINSAzanubrutinib cap 80 mg
    CABOMETYXcabozantinib S-malate tab (various strengths)
    COPIKTRAduvelisib cap 15 mg; 25 mg
    AUGTYROrepotrectinib cap 40 mg; 160 mg
    ALECENSAalectinib (mg base equivalent) listed
    ALUNBRIGbrigatinib tab (30 mg; 90 mg; 180 mg) and initiation pack
    COMETRIQcabozantinib s-mal cap kit
    Abbreviation to Drug Name Mappingsmixed
    ALUNBRIGbrigatinib tab 30 mg; 90 mg; 180 mg
    COMETRIQcabozantinib s-mal cap x 80 mg & 3 x 20 mg (140 dose) kit
    AUGTYROrepotrectinib cap 40 mg; 160 mg
    COPIKTRAduvelisib cap 15 mg; 25 mg
    AVMAPKI FAKZYNJA CO-PACKavutometinib cap 0.8 mg & defactinib tab 200 mg therapy
    AYVAKITavapritinib tab 25 mg, 50 mg, 100 mg, 200 mg, 300 mg
    COTELLICcobimetinib fumarate tab 20 mg (base equivalent)
    BALVERSAerdafitinib tab 3 mg, 4 mg, 5 mg
    BESREMIropeginterferon alfa-2b soln prefilled syr 500 mcg/ml
    cyclophosphamidetab 50 mg; cap 25 mg
    1–10 of 39
    1/4
    Drug name mappings (examples)NDC|mixed
    methotrexate sodium inj 50 mg/2ml (25 mg/ml), 250 mg/10mlmethotrexate sodium injection formulations listed in abbreviation key
    methotrexate sodium inj pf 1000 mg/40ml (25 mg/ml)preservative-free methotrexate injection formulation listed
    methotrexate sodium tab 2.5 mg (base equiv)oral methotrexate tablet strength
    Additional drug mappingsNDC|mixed
    PIQRAY alpelisib tab 200 mg/300 mgalpelisib tablet pack daily dose entries
    QINLOCK ripretinib tab 50 mgripretinib tablet strength
    TALZENNA talazoparib tosylate tab 40 mg, 80 mg; cap 0.1 mg, 0.25 mg, 0.35 mg, 0.5 mgtalazoparib strengths and formulations
    strengths/packaging examples
    Examples of tablet strengths30 mg; 90 mg; 180 mg (e.g., brigatinib ALUNBRIG)
    Examples of oral solution / suspension strengths10 mg/mL; 25 mg/mL; 200 mg/5 mL; 400 mg/mL (e.g., itraconazole oral soln 10 mg/mL; levofloxacin soln 25 mg/mL; acyclovir susp 200 mg/mL; itraconazole delayed-release packets)
    Examples of capsule / tablet strengths for anti-infectives50 mg; 100 mg; 150 mg; 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 750 mg
    Examples of pack / packet presentationspellet packs and packet formulations (e.g., sofosbuvir-velpatasvir pellet packs 150-37.5 mg; 200-50 mg; posaconazole DR suspension packets)
    Examples of injectable / prefilled syringe concentrations50 mg/2 mL (25 mg/mL); 500 mcg/mL (ropeginterferon prefilled syringes); 0.5 mL syringes for vaccines

    Authorization, Step Therapy & Submission Notes

    Prior Authorization

    Prior Authorization Required

    Your prescription drug plan requires prior authorization (PA) for certain drugs. If PA is commonly required for a drug listed in this formulary, it will be noted with an indicator in the Prior Authorization column next to that drug. Failure to obtain required prior authorization may result in the drug not being covered. Some plans may require PA for additional drugs beyond those noted here; providers and members should refer to the member's specific prescription plan materials and Benefit Booklet (Certificate of Coverage) for details.

    • Prior Authorization (PA) required for certain drugs — providers must submit a PA request for coverage prior to dispensing when indicated.
    • Drugs requiring PA are marked in the Prior Authorization column in the formulary or search results.
    • Failure to obtain PA when required may result in non-coverage of the drug.
    Note

    Informational — Abbreviation Mappings

    This section primarily lists abbreviation mappings and drug-name/key entries. It is informational only and does not specify additional provider actions, documentation requirements, or step therapy rules beyond indicating where UM program indicators (Prior Authorization, Step Therapy, Quantity Limits) will appear in the formulary columns.

    • Section content = abbreviation key and drug listing examples.
    • No provider documentation or submission procedures are specified in this abbreviation/key section.
    • This section lists abbreviation keys and mapping examples (dosage forms, codes such as GP, GN, BP, BN, NC, specialty markers).
    Step Therapy

    Step Therapy — No Specific Rules in This Section

    Step therapy (ST) may apply to certain drugs in the prescription drug plan and, when commonly required for drugs, will be noted with an indicator in the Step Therapy column next to those drugs. However, no step therapy rules or step-therapy-specific provider actions are detailed in this abbreviation/key excerpt.

    • Step Therapy (ST) is described generally: members may need to try a proven, cost-effective alternative before coverage of the requested drug is available.
    • No specific step therapy rules, pathways, or prior step requirements are provided in this section.
    • If a drug is subject to step therapy it will be indicated in the formulary (Step Therapy column).
    Documentation Required

    Nonformulary Exception — Provider Action

    Nonformulary drugs are not covered unless approved through the nonformulary consideration (formulary exception) process. Providers may submit a nonformulary consideration request on a member's behalf. This informational excerpt does not include the submission form, criteria, or documentation details for nonformulary exception requests.

    • Providers can submit nonformulary (formulary exception) requests for members.
    • This section does not provide the procedural steps, forms, or required clinical documentation for exception requests — refer to the member's prescription plan materials for procedure details.
    Note

    No Additional Provider Actions Specified in This Section

    No additional provider actions, documentation requirements, authorization procedures, or denial criteria are specified within these abbreviation-key chunks beyond the general notes above. For operational details (how to submit PA or exception requests, required clinical documentation, and any plan-specific UM rules), providers should consult the member's prescription plan materials or contact the plan's pharmacy benefit manager.

    • This section contains abbreviation mappings and drug name entries only — no PA submission steps, required forms, or denial triggers are provided here.
    • Refer to the plan's UM materials or PBM (Prime Therapeutics on behalf of Capital Blue Cross) for specific authorization submission instructions and documentation requirements.

    Abbreviations & Key Terms

    Specialty drugs — definition and distribution notes
    DefinitionSpecialty drugs: medications used to treat complex conditions (e.g., hepatitis, multiple sclerosis, rheumatoid arthritis) that may be oral or injectable and are distributed through the plan's specialty pharmacy provider (Accredo).
    DistributionSpecialty drugs are distributed through the plan's specialty pharmacy (Accredo); some are limited distribution and available only from select pharmacies.
    Supply limitSpecialty drugs are limited to a 30-day supply (plan standard).
    P&T Committee — definition
    DefinitionP&T Committee: Pharmacy and Therapeutics Committee composed of providers and pharmacists that reviews FDA-regulated prescription drugs for safety, efficacy, and tier placement; meets at least annually and reviews new FDA approvals.
    Abbreviation key — common shorthand tokens
    mgmilligram
    mlmilliliter
    tab_tablets
    susp_suspension
    capcapsules
    Abbreviation key mapping (GN, GP, GPI, BP) to drug entries
    GNGeneric name or generic formulation label used to map generic drug entries (example: erythromycin tab delayed release 250 mg; 333 mg; 500 mg).
    BPBrand Preferred / Brand-related label used for brand product entries (example: DELSTRIGO doravirine-lamivudine-tenofovir df tab 100-300-300 mg marked BP).
    GPIGroup product identifier used in abbreviation mappings for specific formulations or packs (seen across antiretroviral and other groups).
    Abbreviation key mapping shorthand tokens to full drug names and dosage forms
    DELSTRIGOdoravirine–lamivudine–tenofovir DF tablet 100-300-300 mg (brand entry) — tab presentation
    DESCOVYemtricitabine–tenofovir alafenamide fumarate tablet 120-15 mg (and other strengths) — tab presentation
    TRUVADAemtricitabine–tenofovir disoproxil fumarate tablet various strength packs (e.g., 100-150 mg; 133-200 mg; 167-250 mg) — tab presentation
    Abbreviation key — shorthand labels associated with formulations
    BNBrand non-preferred / Brand notation used in abbreviation mappings (appears with some entries).
    BPBrand preferred notation used in abbreviation mappings (appears with patented brand entries).
    GNGeneric notation used to indicate generic formulations in mappings; often used for multiple strengths/formulations.
    Abbreviation key — mapping tokens to full drug names with dosage forms and strengths
    ALUNBRIGbrigatinib tablets — 30 mg; 90 mg; 180 mg (tab)
    COMETRIQcabozantinib S-malate capsule/kit (example pack: 1 x 80 mg & 3 x 20 mg) — cap
    METHOTREXATE SODIUMmethotrexate sodium injection formulations — 50 mg/2 mL (25 mg/mL); 250 mg/10 mL; preservative-free 1000 mg/40 mL listed
    Abbreviation key (vaccine products) — product name, formulation, dose/presentation
    COMIRNATY 2025-26COVID-19 mRNA vaccine (Pfizer) — im suspension prefilled syringe 30 mcg/0.3 mL
    GARDASIL 9human papillomavirus (HPV) 9‑valent recombinant vaccine — im suspension
    PREVNAR 20pneumococcal 20‑valent conjugate vaccine — suspension syringe 0.5 mL
    Abbreviation key mapping short labels to full drug/vaccine product names and presentation
    CAPVAXIVEpneumococcal 21‑valent conjugate vaccine — solution syringe 0.5 mL
    FLUZONE HIGH‑DOSE 2025-26influenza vaccine split high‑dose — suspension syringe 0.5 mL
    MODERNA COVID‑19 VACCINEmRNA COVID‑19 vaccine (Moderna) — multiple presentations noted (prefilled syringes)
    Abbreviation key — example mapping (selected oncology agents)
    ALUNBRIGbrigatinib tablet — 30 mg; 90 mg; 180 mg; initiation pack available
    AUGTYROrepotrectinib capsule — 40 mg; 160 mg
    COPIKTRAduvelisib capsule — 15 mg; 25 mg
    Abbreviation key / Drug mapping — example oncology oral agents
    KISQALIribociclib succinate tablets — pack/daily-dose entries (e.g., 200 mg daily dose pack referenced)
    JAYPIRCApirtobrutinib tablets — 50 mg; 100 mg
    LENVIMAlenvatinib capsules — therapy packs referenced for various daily doses
    Abbreviation key mapping to full drug names, formulations, strengths, brand names
    XALKORIcrizotinib capsules — 200 mg; 250 mg
    TAFINLARdabrafenib mesylate tablets/for oral suspension — 10 mg and other tablet strengths
    TALZENNAtalazoparib tosylate tablets — 40 mg; 80 mg
    Abbreviation key mapping brand/generic names to dosage forms and strengths
    Vancomycin (Vancocin/Firvanq)oral solution and oral formulations — example listed (Vancocin)
    Fosfomycinfosfomycin tromethamine powder pack 3 g (single‑dose pack)
    Albendazole (Albenza)albendazole tablet 200 mg — antiparasitic example in key
    Abbreviation key mapping shorthand codes to full product names for hormonal therapies
    Estrogen-progestin combined formulationsdesogestrel & ethinyl estradiol tablets (e.g., 0.15 mg/30 mcg) and drospirenone‑ethinyl estradiol‑levomefolate (Beyaz) — oral tablets
    Medroxyprogesterone acetate (Depo‑Provera)IM suspension prefilled syringe 150 mg/mL — contraceptive injectable presentation
    Testosterone formulationstestosterone cypionate IM injection 100 mg/mL and 200 mg/mL; transdermal gels and solutions (examples listed)
    Abbreviation key mapping shorthand entries to drug names and formulations
    Erythromycinerythromycin ethylsuccinate suspension 400 mg/mL; delayed‑release tablets 250 mg, 333 mg, 500 mg
    Itraconazoleitraconazole oral solution 10 mg/mL; itraconazole capsule 100 mg (Sporanox)
    Ketoconazoleketoconazole tablets 200 mg

    Supply Limits & Specialty Drug Supply

    specialty drugs (general) — standard specialty supply (days)
    Standard specialty supply30-day supply for specialty drugs
    Maintenance drug supply optionsMaintenance drugs commonly available in 30- or 90-day supplies (plan dependent)
    Quantity Level Limits (QLL)Certain drugs have QLLs noted with a dot in the quantity level limits column; exceeding the QLL may result in member responsibility for excess cost.

    Administration & Billing Notes

    Billing Rule

    Bill non–self-administered injectables to medical benefit / contact Accredo

    Injectable drugs that are not routinely self-administered may be billed under the member's medical benefit; Accredo can provide select medical injectable drugs and can be contacted for distribution and billing information.

    • Contact Accredo at 833.721.1626 (TTY: 711) or fax 888.302.1028 for information on service and billing.
    • Self-administered injectable drugs are usually covered under the prescription benefit; non–self-administered injectables may be medical benefit.

    Policy Background

    Specialty drugs treat complex conditions (for example, hepatitis, multiple sclerosis, and rheumatoid arthritis) and may be oral or injectable. Distribution and management of specialty therapies are administered through the plan’s specialty pharmacy (Accredo) for many products; some specialty agents are designated as limited distribution and must be obtained from specific pharmacies. Standard supply expectations note a 30-day specialty supply with maintenance drug options commonly available as 30- or 90-day supplies. Providers should prescribe formulary agents when appropriate and may submit a nonformulary (formulary exception) request if a formulary alternative is not suitable. Utilization management programs such as prior authorization, step therapy, and quantity level limits (QLL) apply where indicated on the formulary.